Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aviscumine (CY-503) in Advanced Melanoma
NCT00658437Phase 2Completed
- Sponsor
- Cytavis BioPharma
- Start
- Apr 2008
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aviscumine in melanoma, sponsored by Cytavis BioPharma. Primary endpoints: Progression-Free Survival at 8 weeks and Overall Survival at 1 year. Started Apr 2008; status: completed.
02
Drugs
aviscumine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00658437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658437.